Royalty Pharma (RPRX) Net Cash Flow (2019 - 2026)

Royalty Pharma (RPRX) has 8 years of Net Cash Flow data on file, last reported at -$32.3 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 120.35% year-over-year to -$32.3 million; the trailing twelve-month figure through Mar 2026 stood at -$501.3 million (down 304.86% YoY), and the FY2025 full-year result was -$310.3 million, down 168.65% from the prior year.
• Net Cash Flow rose to -$32.3 million in Q1 2026, from -$320.2 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $921.6 million in Q2 2024 to a low of -$1.2 billion in Q3 2023.
• A 5-year average of -$56.2 million and a median of $158.7 million in 2025 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow soared 376.84% in 2022 and slumped 1423.1% in 2025, its largest moves.
• Tracing RPRX's Net Cash Flow over 5 years: stood at $719.1 million in 2022, then slumped by 163.89% to -$459.4 million in 2023, then surged by 95.42% to -$21.0 million in 2024, then tumbled by 1423.1% to -$320.2 million in 2025, then soared by 89.91% to -$32.3 million in 2026.
• Business Quant data shows RPRX's Net Cash Flow at -$32.3 million in Q1 2026, -$320.2 million in Q4 2025, and $307.0 million in Q3 2025.